AUM Biosciences key facts
as of Oct 2026- Developer of an oncology-focused biotechnology platform designed to help in harnessing the power of digital and precision medicine.
- AUM Biosciences is valued at approximately $98.7M as of Oct 2026 (last reported valuation).
- It has raised $29.7M; the latest was Later Stage VC in Feb 2026.
- Notable investors include SPRIM Global Investments, ASA Capital Partners, Accelerate Technologies, Agency for Science, Anexa Capital (US) — 9 tracked in total.
- Status: Privately Held (backing).
AUM Biosciences's last reported valuation, Oct 2021. Nothing priced has surfaced since.
- ·Watch AUM Biosciences: the Monday email on marks, rounds and moves
AUM Biosciences funding rounds
No funding rounds for AUM Biosciences are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
AUM Biosciences valuation
AUM Biosciences's last reported valuation was $98.7 million in Oct 2021. No priced round, secondary trade or fund mark has surfaced since.
AUM Biosciences investors
9 investors are on record for AUM Biosciences, including SPRIM Global Investments, ASA Capital Partners, Accelerate Technologies and Agency for Science.
About AUM Biosciences
Developer of an oncology-focused biotechnology platform designed to help in harnessing the power of digital and precision medicine. The company utilizes a proprietary partnered AI-augmented platform to systematically discover and develop targeted cancer therapies focused on genetic targets, enabling patients to access the right medicines at the right time.
- Sector
- Healthcare
- HQ
- Singapore, Singapore
- Founded
- 2018
- Employees
- 19
- Website
- aumbiosciences.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.